Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Modern methods of drug design and development
Lloyd, Matthew.
Cambridge, MA : Academic Press, an imprint of Elsevier, 2023.
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
National Institute for Health and Care Excellence (Great Britain).
[London, England] : National Institute for Health and Care Excellence, 19 January 2022.
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
[London, England] : National Institute for Health and Care Excellence, 14 October 2020.
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
[London, England] : National Institute for Health and Care Excellence, 22 January 2020.
Trastuzumab combination and monotherapy for HER2 advanced or recurrent uterine or endometrial cancer : a review of clinical effectiveness and cost-effectiveness
Gray, Casey; Argáez, Charlene; Canadian Agency for Drugs and Technologies in Health.
Version: 1.0. Ottawa : Canadian Agency for Drugs and Technologies in Health, November 11, 2020.
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
[London, England] : National Institute for Health and Care Excellence, 10 June 2020.
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
[London, England] : National Institute for Health and Care Excellence, 8 May 2019.
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
[London, England] : National Institute for Health and Care Excellence, 20 March 2019.
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
[London, England] : National Institute for Health and Care Excellence, 14 August 2019.
HER2-positive breast cancer
Hurvitz, Sara A, 1970-; McCann, Kelly (Kelly E).
St. Louis, Missouri : Elsevier, [2019]
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
[London, England] : National Institute for Health and Care Excellence, 20 November 2019.
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
[London] : National Institute for Health and Care Excellence, 7 March 2018.
ErbB receptor signaling : methods and protocols
Wang, Zhixiang, (Professor of medical genetics).
New York : Humana Press, [2017]
Handbook of HER2-targeted agents in breast cancer
Alvarez, Ricardo H.
Second edition. [Cham] : Adis, Springer International Publishing AG Switzerland, [2016].
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
[London] : National Institute for Health and Care Excellence, October 26, 2016.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
[London] : National Institute for Health and Care Excellence, December 21, 2016.
Grundlagen und moderne Aspekte der HER2-Diagnostik
Kurbacher, Christian M.
Bremen : UNI-MED Verlag AG, [2015]
Guide to targeted therapies. Treatment resistance in lung cancer
Cappuzzo, Federico.
Cham : Adis, [2015]
Filters: Manage Filters